Assays and Strategies for Targeted Protein Degradation Development
Targeted Protein Degradation (TPD) is an emerging drug modality that enables specific degradation of protein targets, offering a powerful approach to tackle previously undruggable targets including KRAS, transcription factors, and complex protein assemblies. Unlike traditional small molecule inhibitors or monoclonal antibodies, TPD therapeutics provide a unique mechanism that specifically and rapidly eliminates the target protein of interest.
Developing TPD therapeutics requires specialized assays to interrogate each critical step, from degrader discovery and ternary complex formation through target ubiquitination, degradation, and phenotypic response. In this Teach Me in 10, Dr. Sam Jensen provides a comprehensive overview of the tools, assays and strategies needed at each stage of the TPD discovery and development workflow.
Watch this episode to understand:
- How emerging degrader modalities are overcoming traditional drug discovery limitations and opening new therapeutic possibilities
- Approaches for degrader discovery, ternary complex confirmation, ubiquitination profiling, and assessing on- and off-target effects
- Techniques to accelerate translational research by streamlining degrader development and reducing experimental uncertainty
Further resources:
- Tools for Proximity-Induced Targeted Protein Degradation
- Webinar: Targeted Protein Degradation: Controlling and Assessing Therapeutic Targets to Advance Oncology Drug Discovery
- Custom Antibody Conjugation & Labeling Services
- Proteomics Analytical Services
- 3x the Data, 3x the Insights: What's the Difference Between DIA & DDA Proteomics?
